Cardima To Present At The First International Conference On Medical Implants.Business Editors/Health/Medical Writers FREMONT, Calif.--(BUSINESS WIRE)--July 25, 2003 In its continuing interest to develop innovative therapeutics to treat atrial fibrillation atrial fibrillation Irregular rhythm (arrhythmia) of contraction of the atria (upper heart chambers). The most common major arrhythmia, it may result as a consequence of increased fibrous tissue in the aging heart, of heart disease, or in association with severe infection. (AF) and to foster awareness for the current alternative AF treatments, Cardima(R), Inc. (NasdaqSC: CRDM CRDM Control Rod Drive Mechanism CRDM Centre for Rapid Design and Manufacture (Buckinghamshire Chilterns University) CRDM Cumann Rince Dea Mheasa (Irish dancing organisation) ) will be sponsoring the seminar entitled, "Atrial Fibrillation: Some Medical and Surgical Perspectives," at the First International Conference on Medical Implants. The course organizer, Salim Aziz, M.D., of Washington Adventist Hospital, Maryland, has arranged an internationally renowned faculty to cover medical and surgical aspects of atrial fibrillation. Marc Wish, M.D., Arrhythmia arrhythmia (ārĭth`mēə), disturbance in the rate or rhythm of the heartbeat. Various arrhythmias can be symptoms of serious heart disorders; however, they are usually of no medical significance except in the presence of Associates and Professor Ernst G. Vester, Dusseldorf, Germany will address Cardima's approach to treating AF in two presentations entitled, "A right sided catheter approach" and "A left-sided approach to treat atrial fibrillation using multi-polar microcatheters." The conference will be held at the Hyatt Regency in Bethesda, MD on July 26, 2003. Presentations will include aspects of emerging minimally invasive techniques to treat atrial fibrillation. About Cardima Cardima, Inc. has developed the REVELATION(R) Tx, REVELATION(R) T-Flex and REVELATION(R) Helix linear ablation ablation /ab·la·tion/ (-shun) 1. separation or detachment; extirpation; eradication. 2. removal or destruction, especially by cutting. ab·la·tion n. microcatheter systems for the minimally invasive treatment of atrial fibrillation (AF). The REVELATION(R) Helix was developed for the treatment of AF originating in the pulmonary veins of the heart. The REVELATION(R) Tx, REVELATION(R) T-Flex and REVELATION(R) Helix systems have received CE Mark approval in Europe and received approval in Canada in January 2003. The Company has also developed a Surgical Ablation System, which is expected to be used by cardiac surgeons for the treatment of AF, to ablate ab·late v. To remove or destroy the function of. ablate to remove, especially by cutting. ablate verb To remove; excise cardiac tissue during heart surgery using radio frequency (RF) energy. In February 2003, the Company announced that it had received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. 510(k) clearance to market the Surgical Ablation System in the U.S. Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include the Company's ability to raise additional capital, whether the Company's pre-market approval (PMA PMA (papillary-marginal-attached), n a system of epidemiologic scoring of periodontal disease devised by Schour and Massler in which the symbols denote the areas involved in gingival inflammation. PMA Progressive muscular atrophy ) application for the REVELATION(R) Tx or any other product will be approved by the FDA, the possibility of business disruption or unanticipated expenses due to the Company's recent staffing reduction, and whether the Company will be able to conduct successful clinical trials, obtain and maintain regulatory approvals, gain acceptance for its products from the marketplace, secure distribution partners or successfully market, sell and distribute its products to end users in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , in the event FDA approval is obtained, or in other markets. Additional risks are set forth in the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2002, filed with the Securities and Exchange Commission on March 31, 2003, and the Company's Quarterly Report on Form 10-Q Form 10-Q See 10-Q. for the quarter ended March 31, 2003. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion